Nina N Sanford1, Beow Y Yeap2, Mykol Larvie3, Juliane Daartz1, John E Munzenrider1, Norbert J Liebsch1, Barbara Fullerton4, Elizabeth Pan1, Jay S Loeffler1, Helen A Shih5. 1. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. 5. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: hshih@mgh.harvard.edu.
Abstract
PURPOSE: To assess the outcomes of benign meningiomas (BM) treated to two radiation dose levels. METHODS AND MATERIALS: We randomly assigned patients (1:1) with incompletely resected or recurrent BM to 2 radiation doses: 55.8 Gy(relative biological effectiveness [RBE]) and 63.0 Gy(RBE) of fractionated combined proton-photon radiation therapy. The primary endpoint was local control with hypothesis of improved tumor control with higher dose. Secondary endpoints included progression-free survival, overall survival, and rates of treatment-related toxicities. RESULTS:Between 1991 and 2000, 47 patients were randomized. Three patients were excluded for nonbenign histology; therefore, 44 patients were analyzed: 22 who received 55.8 Gy(RBE) and 22 who received 63.0 Gy(RBE). The median follow-up was 17.1 years. Local control for the entire cohort was 98% at 10 years and 90% at 15 years. Of the 5 patients with local recurrence, 4 occurred after 10 years of follow-up, and 3 were in the lower dose group (P=.322). In the modified intention to treat analysis, there was no difference in progression-free survival (P=.234) and overall survival (P=.271) between arms. A total of 26 patients (59%) experienced a grade 2 or higher late toxicity, including 9 patients (20%) incurring a cerebrovascular accident (CVA), 7 of which were deemed at least possibly attributable to irradiation. The median time between completion of radiation therapy and CVA was 5.6 years (range, 1.4-14.0 years). CONCLUSIONS:Fractionated combined proton-photon radiation therapy is effective for BM, with no apparent benefit in dose escalation. Further investigation is needed to better define the risk of late toxicities, including CVA after cranial radiation therapy.
RCT Entities:
PURPOSE: To assess the outcomes of benign meningiomas (BM) treated to two radiation dose levels. METHODS AND MATERIALS: We randomly assigned patients (1:1) with incompletely resected or recurrent BM to 2 radiation doses: 55.8 Gy(relative biological effectiveness [RBE]) and 63.0 Gy(RBE) of fractionated combined proton-photon radiation therapy. The primary endpoint was local control with hypothesis of improved tumor control with higher dose. Secondary endpoints included progression-free survival, overall survival, and rates of treatment-related toxicities. RESULTS: Between 1991 and 2000, 47 patients were randomized. Three patients were excluded for nonbenign histology; therefore, 44 patients were analyzed: 22 who received 55.8 Gy(RBE) and 22 who received 63.0 Gy(RBE). The median follow-up was 17.1 years. Local control for the entire cohort was 98% at 10 years and 90% at 15 years. Of the 5 patients with local recurrence, 4 occurred after 10 years of follow-up, and 3 were in the lower dose group (P=.322). In the modified intention to treat analysis, there was no difference in progression-free survival (P=.234) and overall survival (P=.271) between arms. A total of 26 patients (59%) experienced a grade 2 or higher late toxicity, including 9 patients (20%) incurring a cerebrovascular accident (CVA), 7 of which were deemed at least possibly attributable to irradiation. The median time between completion of radiation therapy and CVA was 5.6 years (range, 1.4-14.0 years). CONCLUSIONS: Fractionated combined proton-photon radiation therapy is effective for BM, with no apparent benefit in dose escalation. Further investigation is needed to better define the risk of late toxicities, including CVA after cranial radiation therapy.
Authors: Mark W McDonald; David A Plankenhorn; Kevin P McMullen; Mark A Henderson; Edward J Dropcho; Mitesh V Shah; Aaron A Cohen-Gadol Journal: J Neurooncol Date: 2015-04-10 Impact factor: 4.130
Authors: S Vatnitsky; J Siebers; D Miller; M Moyers; M Schaefer; D Jones; S Vynckier; Y Hayakawa; S Delacroix; U Isacsson; J Medin; A Kacperek; A Lomax; A Coray; H Kluge; J Heese; L Verhey; I Daftari; K Gall; G Lam; T Beck; G Hartmann Journal: Radiother Oncol Date: 1996-11 Impact factor: 6.280
Authors: Lucille D A Dorresteijn; Arnoud C Kappelle; Willem Boogerd; Willem J Klokman; Alfons J M Balm; Ronald B Keus; Flora E van Leeuwen; Harry Bartelink Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Erin Arthurs; Timothy P Hanna; Khaled Zaza; Yingwei Peng; Stephen F Hall Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-17 Impact factor: 7.038
Authors: Dimitri Vanmarcke; Johan Menten; Gilles Defraene; Frank Van Calenbergh; Steven De Vleeschouwer; Maarten Lambrecht Journal: J Neurooncol Date: 2021-01-04 Impact factor: 4.130
Authors: Jiheon Song; Saif Aljabab; Lulwah Abduljabbar; Yolanda D Tseng; Jason K Rockhill; James R Fink; Lynn Chang; Lia M Halasz Journal: J Neurooncol Date: 2021-04-22 Impact factor: 4.130
Authors: Rami A El Shafie; Maja Czech; Kerstin A Kessel; Daniel Habermehl; Dorothea Weber; Stefan Rieken; Nina Bougatf; Oliver Jäkel; Jürgen Debus; Stephanie E Combs Journal: Radiat Oncol Date: 2018-03-27 Impact factor: 3.481